X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

June 27, 2019

Industry Trends in Biologic Formulations

In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.
Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}